Randomized clinical trial of perioperative cefoxitin in preventing maternal infection after primary cesarean section.
To determine the efficacy of perioperative cefoxitin in preventing infections after primary cesarean section, a randomized placebo-controlled, double-blind clinical trial was performed. Among 266 participants, those who received three perioperative 2 gm doses of cefoxitin (138) had significantly fewer serious infections (19.5% vs. 4.3%), fewer urinary tract infections (10.7% vs. 4.4%), less standard febrile morbidity (9.4% vs. 3.6%), and fewer courses of antibiotics postoperatively (23.4% vs. 11.6%). There was no reduction in the length of hospitalization. Use of perioperative cefoxitin umbilical cord is clamped are safe and efficacious in preventing infection after primary cesarean section.
D002440:Cefoxitin / Q000627:therapeutic use*; D002585:Cesarean Section; D002986:Clinical Trials as Topic; D004716:Endometritis / Q000517:prevention & control; D005260:Female; D005334:Fever / Q000517:prevention & control; D006801:Humans; D007231:Infant, Newborn; D007430:Intraoperative Care; D011182:Postoperative Care; D011247:Pregnancy; D011446:Prospective Studies; D011645:Puerperal Infection / Q000517:prevention & control*; D011897:Random Allocation; D018805:Sepsis / Q000517:prevention & control; D014552:Urinary Tract Infections / Q000517:prevention & control
D002440:Cefoxitin